Not too risky over the long term IMO.
Looks like they will take around 50% of the prostate imaging market but their therapy candidate's good results are only based upon one patient's complete response so far.
I reckon it gets bought out shortly anyway.
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS, page-138
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.18 |
Change
-0.600(3.03%) |
Mkt cap ! $6.418B | |||
| Open | High | Low | Value | Volume |
| $18.90 | $19.21 | $18.04 | $51.74M | 2.756M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 710 | $19.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.20 | 7058 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |